Fiche publication
Date publication
août 2022
Journal
Progress in biomedical engineering (Bristol, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ALEM-MARCHAND Halima
Tous les auteurs :
Baka Z, Stiefel M, Figarol A, Godier C, Mallick A, Joubert O, Ashammakhi N, Gaffet E, Alem H
Lien Pubmed
Résumé
Conventional 2D cell cultures are widely used for the development of new anticancer drugs. However, their relevance asmodels is increasingly questioned as they are considered too simplistic compared to complex, three-dimensionaltumors. Moreover, animal experiments are not only costly and time-consuming, but also raise ethical issues and their use for some applications has been restricted. Therefore, it becomes crucial to develop new experimental models that better capture the complexity and dynamic aspects oftumors. New approaches based on microfluidic technology are promising. This technology has indeed been used to create microphysiological systems called 'organ-on-chip' which simulate key structural and functional features of human tissues and organs. These devices have further been adapted to create cancer models giving rise to the 'cancer-on-chip' (COC) concept. In this review, we will discuss the main COC models described so far for major cancer types including lung, prostate, breast, colorectal, pancreatic, and ovarian cancers. Then, we will highlight the challenges that this technology is facing and the possible research perspectives that can arise from them.
Mots clés
cancer-on-chip (COC), in vitro tumor models, microfluidic technology, nanomedicine
Référence
Prog Biomed Eng (Bristol). 2022 08 1;4(3):
